181 related articles for article (PubMed ID: 14613320)
1. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
Sanders JM; Gómez AO; Mao J; Meints GA; Van Brussel EM; Burzynska A; Kafarski P; González-Pacanowska D; Oldfield E
J Med Chem; 2003 Nov; 46(24):5171-83. PubMed ID: 14613320
[TBL] [Abstract][Full Text] [Related]
2. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Ling Y; Sahota G; Odeh S; Chan JM; Araujo FG; Moreno SN; Oldfield E
J Med Chem; 2005 May; 48(9):3130-40. PubMed ID: 15857119
[TBL] [Abstract][Full Text] [Related]
4. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents.
Kotsikorou E; Oldfield E
J Med Chem; 2003 Jul; 46(14):2932-44. PubMed ID: 12825934
[TBL] [Abstract][Full Text] [Related]
5. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
6. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
Ghosh S; Chan JM; Lea CR; Meints GA; Lewis JC; Tovian ZS; Flessner RM; Loftus TC; Bruchhaus I; Kendrick H; Croft SL; Kemp RG; Kobayashi S; Nozaki T; Oldfield E
J Med Chem; 2004 Jan; 47(1):175-87. PubMed ID: 14695831
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase.
Kotsikorou E; Song Y; Chan JM; Faelens S; Tovian Z; Broderick E; Bakalara N; Docampo R; Oldfield E
J Med Chem; 2005 Sep; 48(19):6128-39. PubMed ID: 16162013
[TBL] [Abstract][Full Text] [Related]
8. Activity of sulfonium bisphosphonates on tumor cell lines.
Zhang Y; Hudock MP; Krysiak K; Cao R; Bergan K; Yin F; Leon A; Oldfield E
J Med Chem; 2007 Nov; 50(24):6067-79. PubMed ID: 17963374
[TBL] [Abstract][Full Text] [Related]
9. An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Szabo CM; Martin MB; Oldfield E
J Med Chem; 2002 Jul; 45(14):2894-903. PubMed ID: 12086477
[TBL] [Abstract][Full Text] [Related]
10. The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
[TBL] [Abstract][Full Text] [Related]
11. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
12. Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
Martin MB; Sanders JM; Kendrick H; de Luca-Fradley K; Lewis JC; Grimley JS; Van Brussel EM; Olsen JR; Meints GA; Burzynska A; Kafarski P; Croft SL; Oldfield E
J Med Chem; 2002 Jul; 45(14):2904-14. PubMed ID: 12086478
[TBL] [Abstract][Full Text] [Related]
13. An investigation of bisphosphonate inhibition of a vacuolar proton-pumping pyrophosphatase.
Szabo CM; Oldfield E
Biochem Biophys Res Commun; 2001 Sep; 287(2):468-73. PubMed ID: 11554752
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate inhibition of phosphoglycerate kinase: quantitative structure-activity relationship and pharmacophore modeling investigation.
Kotsikorou E; Sahota G; Oldfield E
J Med Chem; 2006 Nov; 49(23):6692-703. PubMed ID: 17154500
[TBL] [Abstract][Full Text] [Related]
15. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.
Chandrasekaran V; McGaughey GB; Cavallito CJ; Bowen JP
J Mol Graph Model; 2004 Sep; 23(1):69-76. PubMed ID: 15331055
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates.
Cheng F; Oldfield E
J Med Chem; 2004 Oct; 47(21):5149-58. PubMed ID: 15456258
[TBL] [Abstract][Full Text] [Related]
19. CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents.
Murugesan V; Prabhakar YS; Katti SB
J Mol Graph Model; 2009 Feb; 27(6):735-43. PubMed ID: 19117780
[TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
